Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2004-07-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.0403390101PMID 15235125PMCID PMC490000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.

  2004cited by this paper
• Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere)

  2004cited by this paper
• Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer

  2003cited by this paper
• RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells.

  2003cited by this paper
• Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.

  2003cited by this paper
• Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Specific protection against breast cancers by cyclin D1 ablation

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Mechanism of action of anti-HER2 monoclonal antibodies.

  2001cited by this paper
• Clinical trials of Herceptin(R) (trastuzumab).

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

  2000cited by this paper
• The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

  2000cited by this paper
• RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

  2000cited by this paper
• Transcriptional targeting of the HER-2/neu oncogene.

  2000cited by this paper
• ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

  2000cited by this paper
• Synthesis and antitumor activity of an inhibitor of fatty acid synthase.

  2000cited by this paper
• Selective activation of the fatty acid synthesis pathway in human prostate cancer

  2000cited by this paper
• Fatty Acid Synthase (Fas) Predictive Strength in Poorly Differentiated Early Breast Carcinomas

  1999cited by this paper
• Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins.

  1997cited by this paper
• Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma.

  1997cited by this paper
• Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival.

  1997cited by this paper
• Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients

  1996cited by this paper
• Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells.

  1996cited by this paper
• Fatty acid synthesis: a potential selective target for antineoplastic therapy.

  1994cited by this paper
• Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation.

  1994cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease.

  1989cited by this paper
• Expression of haptoglobin-related protein and its potential role as a tumor antigen.

  1989cited by this paper
• What is synergy?

  1989cited by this paper
• Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase.

  1986cited by this paper
• The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis.

  1976cited by this paper
• Fatty acid synthase from rabbit mammary gland.

  1975cited by this paper
• Inhibition of fatty acid synthetases by the antibiotic cerulenin.

  1972cited by this paper

• TARGETING HUMAN FATTY ACID SYNTHASE IN CANCER THERAPY: STRUCTURAL INSIGHTS AND SAR OF DOMAIN SPECIFIC INHIBITOR

  2026cites this paper
• Discovery of mangiferin lipophilic amide derivatives as novel fatty acid synthase inhibitors with potent anti-hepatocellular carcinoma activity.

  2026cites this paper
• LDLR-targeted orlistat therapeutic nanoparticles: Peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines.

  2025cites this paper
• Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

  2025cites this paper
• Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment

  2025cites this paper
• Salivary gamma-glutamyltransferase activity as an indicator of redox homeostasis in breast cancer

  2025cites this paper
• Targeting Lipid Transport Pathways: A New Frontier in Colorectal Cancer Therapy

  2025cites this paper
• CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

  2025cites this paper
• Metabolic hallmarks of trastuzumab resistance

  2025influential citation
• Multiomics and single‐cell sequencings reveal the specific biological characteristics of low Ki‐67 triple‐negative breast cancer

  2024cites this paper
• Fatty acid synthase: A key driver of ovarian cancer metastasis and a promising therapeutic target.

  2024cites this paper
• Emerging targets in lipid metabolism for cancer therapy.

  2024cites this paper
• Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer.

  2024cites this paper
• A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance

  2024cites this paper
• Deubiquitinases and Cancer

  2024cites this paper
• Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype

  2024cites this paper
• Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy

  2024cites this paper
• The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification

  2024cites this paper
• Liver X Receptor Ligand GAC0001E5 Downregulates Antioxidant Capacity and ERBB2/HER2 Expression in HER2-Positive Breast Cancer Cells

  2024influential citation
• Genome-scale modeling identifies dynamic metabolic vulnerabilities during the epithelial to mesenchymal transition

  2024cites this paper
• IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy

  2024cites this paper
• Exploring the significance of fatty acid metabolism reprogramming in the pathogenesis of cancer and anticancer therapy

  2024cites this paper
• Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor

  2023cites this paper
• Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

  2023cites this paper
• Prognosis and Characterization of Microenvironment in Cervical Cancer Influenced by Fatty Acid Metabolism-Related Genes

  2023cites this paper
• Lipid metabolism in malignant tumor brain metastasis: reprogramming and therapeutic potential

  2023cites this paper
• Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer

  2023cites this paper
• Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence

  2023cites this paper
• Lipid metabolism as a target for cancer drug resistance: progress and prospects

  2023cites this paper
• Extracellular vesicles as mediators of cell-cell communication in ovarian cancer and beyond - A lipids focus.

  2023cites this paper
• Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations

  2023cites this paper
• Inter-organelle cross-talk supports acetyl-coenzyme A homeostasis and lipogenesis under metabolic stress

  2023cites this paper
• Fatty acid synthase: a druggable driver of breast cancer brain metastasis

  2022influential citation
• Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets

  2022cites this paper
• Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs

  2022cites this paper
• Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients

  2022cites this paper
• Emerging roles of fatty acid metabolism in cancer and their targeted drug development.

  2022cites this paper
• An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer

  2022cites this paper
• Metabolic targeting of malignant tumors: a need for systemic approach

  2022cites this paper
• Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas

  2022cites this paper
• Relationship between metabolic reprogramming and drug resistance in breast cancer

  2022cites this paper
• Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications

  2022cites this paper
• Resistance to Trastuzumab

  2022cites this paper
• Constraint-based modeling identifies metabolic vulnerabilities during the epithelial to mesenchymal transition

  2022cites this paper
• Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway

  2022cites this paper
• The relevance of EGFR, ErbB receptors and neuregulins in human adipocytes and adipose tissue in obesity.

  2022cites this paper
• The Heterogeneity of Lipid Metabolism in Cancer.

  2021cites this paper
• Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.

  2021cites this paper
• Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer

  2021cites this paper
• Glucose-sensitive acetylation of Seryl tRNA synthetase regulates lipid synthesis in breast cancer

  2021cites this paper
• Expanding Roles of De Novo Lipogenesis in Breast Cancer

  2021influential citation
• Fatty Acid Metabolism and Cancer.

  2021cites this paper
• Signaling, metabolism, and cancer: An important relationship for therapeutic intervention

  2021cites this paper
• Reprogramming of fatty acid metabolism in breast cancer: a narrative review

  2021cites this paper
• Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives

  2021cites this paper
• Review on target domains and natural compound‐based inhibitors of fatty acid synthase for anticancer drug discovery

  2021cites this paper
• Unravelling the Anticancer Mechanisms of Traditional Herbal Medicines with Metabolomics

  2021influential citation
• Pharmacological fatty acid synthase inhibitors differently affect the malignant phenotype of oral cancer cells.

  2021cites this paper
• Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells

  2021cites this paper
• Ethanol extract of Ardisiae Japonicae Herba inhibits hepatoma carcinoma cell proliferation in vitro through regulating lipid metabolism

  2021cites this paper
• The Potential Role of Changes in the Glucose and Lipid Metabolic Pathways in Gastrointestinal Cancer Progression: Strategy in Cancer Therapy

  2021cites this paper
• Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity.

  2021cites this paper
• Anastrozole Regulates Fatty Acid Synthase in Breast Cancer

  2021influential citation
• Lipid Metabolism and Resistance to Anticancer Treatment

  2020cites this paper
• Lipid metabolism and cancer

  2020cites this paper
• NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism

  2020cites this paper
• Metabolic Escape Routes of Cancer Stem Cells and Therapeutic Opportunities

  2020cites this paper
• Icaritin reduces prostate cancer progression via inhibiting high-fat diet-induced serum adipokine in TRAMP mice model

  2020cites this paper
• Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

  2020cites this paper
• Effect of neoadjuvant chemotherapy on breast tissue composition: a longitudinal mammographic study with automated volumetric measurement

  2020cites this paper
• Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets.

  2020cites this paper
• NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism

  2020cites this paper
• Cancer metabolism

  2020cites this paper
• Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer

  2020cites this paper
• Metformin : a pharmacological approach integrating hyperinsulinemia and breast cancer at the molecular , cellular and clinical levels *

  2019cites this paper
• SLC 37 A 1 Gene expression is up-regulated by epidermal growth factor in breast cancer cells

  2019cites this paper
• Fluorescent Heterotelechelic Single-Chain Polymer Nanoparticles: Synthesis, Spectroscopy, and Cellular Imaging

  2019cites this paper
• RA-XII Suppresses the Development and Growth of Liver Cancer by Inhibition of Lipogenesis via SCAP-dependent SREBP Supression

  2019cites this paper
• Identifying and targeting cancer-specific metabolism with network-based drug target prediction

  2019cites this paper
• Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics

  2019cites this paper
• Galloyl esters of trans-stilbenes are inhibitors of FASN with anticancer activity on non-small cell lung cancer cells.

  2019cites this paper
• Lipid metabolism and Calcium signaling in epithelial ovarian cancer.

  2019cites this paper
• Targeting Cell Metabolism as Cancer Therapy

  2019cites this paper
• NRF2-dependent metabolic reprogramming is required for tumor recurrence following oncogene inhibition

  2019cites this paper
• Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells

  2019cites this paper
• Reprogramming of fatty acid metabolism in cancer

  2019influential citation
• Towards personalized treatment for early stage HER2-positive breast cancer

  2019cites this paper
• Fatty acid synthase expression in prostatic adenocarcinoma: correlation with Gleason score and specimen type

  2018cites this paper
• De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer

  2018cites this paper
• The Heterogeneity of Lipid Metabolism in Cancer.

  2018cites this paper
• Prognostic role of TPD52 in acute myeloid leukemia: A retrospective multicohort analysis

  2018cites this paper
• Kahweol inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells.

  2018cites this paper
• Down‐regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP‐1c axis

  2018cites this paper
• Fatty acid synthase is required for profibrotic TGF‐β signaling

  2018cites this paper
• Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression

  2018cites this paper
• Lipid metabolism reprogramming and its potential targets in cancer

  2018cites this paper
• Chemical genetics in tumor lipogenesis.

  2018cites this paper
• Interacting Cancer Machineries: Cell Signaling, Lipid Metabolism, and Epigenetics.

  2018cites this paper
• Fatty acid synthase (FASN) as a therapeutic target in breast cancer

  2017influential citation
• Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib

  2017cites this paper